Single-nucleus transcriptomics-based drug screening platform for focal cortical dysplasia.
A transcriptome-guided framework for linking multicellular disease signatures to candidate therapeutic strategies in refractory epilepsy is established, and four compounds reduced seizure-like activity in vivo, as assessed by behavioral assays and local field potential recordings.